1. 746PCOnsensus statement on mandatory measurements in PAncreatic cancer trials for systemic treatment of unresectable disease (COMM-PACT). (18th September 2017) Authors: van Rijssen, L.B.; ter Veer, E.; Besselink, M.G.; Mali, R.M.A.; Berlin, J.; Boeck, S.; Bonnetain, F.; Conroy, T.; Deplanque, G.; Goldstein, D.; Glimelius, B.; Neoptolemos, J.P.; Reni, M.; Scheithauer, W.; van der Meer, J.; Wilmink, J.W.; van der Poel, M.J.; Busch, O.R.; van Oijen, M.G.H.; van Laa... Journal: Annals of oncology Issue: Volume 28(2017)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'. (May 2018) Authors: Haas, M.; Siveke, J.T.; Schenk, M.; Lerch, M.M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T.J.; Kruger, S.; Westphalen, C.B.; Held, S.; Heinemann, V.; Boeck, S. Journal: European journal of cancer Issue: Volume 94(2018) Page Start: 95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Expression of Indoleamine 2, 3-dioxygenase in erlotinib-treated patients with advanced pancreatic cancer: Translational results from a multi-center, randomized phase III trial. (March 2019) Authors: Kruger, S.; Ormanns, S.; Roesgen, V.; Legenstein, M.; Haas, M.; Westphalen, C.B.; Duewell, P.; Schnurr, M.; Kirchner, T.; von Bergwelt-Baildon, M.; Heinemann, V.; Boeck, S. Journal: European journal of cancer Issue: Volume 110(2019)Supplement 1 Page Start: S16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗